Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Publikation

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Wissenschaftlicher Artikel/Review - 13.02.2024

Rech Juergen, Taşçilar Koray, Hagen Melanie, Kleyer Arnd, Manger Bernhard, Schoenau Verena, Hueber Axel J, Kleinert Stefan, Baraliakos Xenofon, Braun Jürgen, Kiltz Uta, Fleck Martin, Rubbert-Roth Andrea, Kofler David M, Behrens Frank, Feuchtenberger Martin, Zaenker Michael, Voll Reinhard E, Venhoff Nils, Thiel Jens, Glaser Cornelia, Feist Eugen, Burmester Gerd R, Karberg Kirsten, Strunk Johannes, Cañete Juan D, Senolt Ladislav, Filkova Maria, Naredo Esperanza, Largo Raquel, Krönke Gerhard, D'Agostino Maria-Antonietta, Østergaard Mikkel, Schett Georg

Zitation

Rech J, Taşçilar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber A, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler D, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester G, Karberg K, Strunk J, Cañete J, Senolt L, Filkova M, Naredo E, Largo R, Krönke G, D'Agostino M, Østergaard M, Schett G. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 2024; 403:850-859.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet 2024; 403

Veröffentlichungsdatum

13.02.2024

eISSN (Online)

1474-547X

Seiten

850-859

Kurzbeschreibung/Zielsetzung

Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain to be developed. We aimed to assess whether 6-month treatment with abatacept improves inflammation in preclinical rheumatoid arthritis.